{
    "Trade/Device Name(s)": [
        "VARIANT II Hemoglobin A1c Program"
    ],
    "Submitter Information": "Bio-Rad Laboratories, Inc.",
    "510(k) Number": "K070452",
    "Predicate Device Reference 510(k) Number(s)": [
        "K984268"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCP",
        "KRZ"
    ],
    "Summary Letter Date": "February 14, 2007",
    "Summary Letter Received Date": "February 16, 2007",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 864.7470"
    ],
    "Regulation Name(s)": [
        "Glycosylated hemoglobin assay"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c"
    ],
    "Specimen Type(s)": [
        "Whole Blood"
    ],
    "Specimen Container(s)": [
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "VARIANT II Hemoglobin Testing System"
    ],
    "Method(s)/Technology(ies)": [
        "Ion-exchange high performance liquid chromatography (HPLC)",
        "Cation exchange chromatography"
    ],
    "Methodologies": [
        "Chromatographic separation"
    ],
    "Submission Type(s)": [
        "Assay",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for Bio-Rad VARIANT II Hemoglobin A1c Program, an HPLC-based assay system for quantifying hemoglobin A1c in EDTA whole blood.",
    "Indications for Use Summary": "Intended for percent determination of hemoglobin A1c in human whole blood to monitor long-term glucose control in individuals with diabetes mellitus.",
    "fda_folder": "Hematology"
}